# Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine

> **NCT00513968** · PHASE1 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **GENETIC:** a mixed plasmid DNA (HB-110)
- **DRUG:** Adefovir

## Key facts

- **NCT ID:** NCT00513968
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-04
- **Final completion:** 2010-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2012-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513968, "Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00513968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*